May 15, 2017
Neuromyelitis Optica (NMO) also termed as Devic’s disease and NMO Spectrum Disorder (NMOSD), is a rare autoimmune demyelinating disorder wherein the antibodies and immune system cells attack the spinal cord and the optic nerve. NMO was once thought of multiple sclerosis (MS), but is now distinguished as exclusive disease with immunopathogenesis and different pathology, which do not respond to conventional MS immunomodulators like interferons.
Ask for Sample copy @ https://www.qyresearchgroups.com/request-sample/203226
The damaged optic never leads to inflammation and swelling and ultimately loss of vision. On the other hand, the damaged spinal cord results in paralysis or weakness in the arms or legs, bladder and bowel troubles and loss of sensation. The reason for NMO in an individual is believed to be because of a particular attack on the aquaporin-4 (AQP4) water channel which is situated within the spinal cord and optic nerves. Aquaporins are proteins which are accountable for water transportation across membranes of the cell. Over 70% of patients with NMO are tested positive for an antibody biomarker in the blood known as the anti-AQP4 or NMO-IgG antibody.
In the United States there are an estimate of nearly 4,000 people with NMO and a quarter-million individuals across the globe. Currently there are no drugs which could completely cure this disorder, instead medications such as rituximab (Rituxan), mycophenolate mofetil (CellCept), azathioprine (Imuran, Azasan), mycophenolate, etc., are prescribed for the maintenance of the therapy. World increasing population is one of the key driving factors of this market industry since the prevalence is more in women than men, approximately 80% higher. Increasing number of geriatric population is also responsible for the market growth. NMO occurs in almost all regions of the world and might be most common in some populations such as Asians, Africans and Native Americans. The Global Neuromyelitis Optica Drug Industry is estimated to grow and garner a substantial CAGR during the forecast period.
The global Neuromyelitis Optica Drug market depending upon its applications is widely bifurcated into two parts, i.e., Remission prophylactic treatment and acute attack. Based on regions, this industry’s market is segmented into Europe (France, Germany, Russia, Italy and UK), North America (Canada, USA and Mexico), Asia Pacific (Korea, China, India, Japan and Southeast Asia), South America, Middle East and Africa. A few of the market players of the global Neuromyelitis Optics Drug market are SANDOZ, FRESENIUS, Intas, Pfizer, Tianjin Kingyork, Gyjtrs, NANG KUANG, Baxter, Grifols, Octapharma, CBOP, TEVA, and CSL.
Get Discount on this Report @ https://www.qyresearchgroups.com/check-discount/203226
Table of Contents
1 Industry Overview of Neuromyelitis Optica Drug
1.1 Definition and Specifications of Neuromyelitis Optica Drug
1.1.1 Definition of Neuromyelitis Optica Drug
1.1.2 Specifications of Neuromyelitis Optica Drug
1.2 Classification of Neuromyelitis Optica Drug
1.3 Applications of Neuromyelitis Optica Drug
1.3.1 Acute attack
1.3.2 Remission prophylactic treatment
1.3.3 Application 3
1.4 Market Segment by Regions
1.4.1 North America
1.4.4 Southeast Asia
2 Manufacturing Cost Structure Analysis of Neuromyelitis Optica Drug
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Neuromyelitis Optica Drug
2.3 Manufacturing Process Analysis of Neuromyelitis Optica Drug
2.4 Industry Chain Structure of Neuromyelitis Optica Drug
3 Technical Data and Manufacturing Plants Analysis of Neuromyelitis Optica Drug
3.1 Capacity and Commercial Production Date of Global Neuromyelitis Optica Drug Major Manufacturers in 2015
Pre Order Enquiry: https://www.qyresearchgroups.com/send-an-enquiry/203226
3.2 Manufacturing Plants Distribution of Global Neuromyelitis Optica Drug Major Manufacturers in 2015
3.3 R&D Status and Technology Source of Global Neuromyelitis Optica Drug Major Manufacturers in 2015
3.4 Raw Materials Sources Analysis of Global Neuromyelitis Optica Drug Major Manufacturers in 2015
4 Global Neuromyelitis Optica Drug Overall Market Overview
4.1 2011-2016 Overall Market Analysis
4.2 Capacity Analysis
4.2.1 2011-2016 Global Neuromyelitis Optica Drug Capacity and Growth Rate Analysis
4.2.2 2015 Neuromyelitis Optica Drug Capacity Analysis (Company Segment)
4.3 Sales Analysis
4.3.1 2011-2016 Global Neuromyelitis Optica Drug Sales and Growth Rate Analysis
4.3.2 2015 Neuromyelitis Optica Drug Sales Analysis (Company Segment)
4.4 Sales Price Analysis
4.4.1 2011-2016 Global Neuromyelitis Optica Drug Sales Price
4.4.2 2015 Neuromyelitis Optica Drug Sales Price Analysis (Company Segment)
5 Neuromyelitis Optica Drug Regional Market Analysis
5.1 North America Neuromyelitis Optica Drug Market Analysis
5.1.1 North America Neuromyelitis Optica Drug Market Overview
QY Research Groups is a company that simplifies how analysts and decision makers get industry data for their business. Our unique colossal technology has been developed to offer refined search capabilities designed to exploit the long tail of free market research whilst eliminating irrelevant results. QY Research Groups is the collection of market intelligence products and services on the Web. We offer reports and update our collection daily to provide you with instant online access to the world's most complete and current database of expert insights on global industries, companies, products, and trends.
Apr 11, 2017
All Copyrights reserve worldhealthcarenews.biz 2017.